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In Vitro Postantibiotic Effect Following Repeated Exposure
to Imipenem, Temafloxacin, and Tobramycin
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The postantibiotic effect (PAE) following three consecutive 2-h exposures to imipenem, temafloxacin, and
tobramycin was determined in Pseudomonas aeruginosa. A PAE and a bactericidal effect were consistently
observed for imipenem following each cycle of drug exposure and regrowth. In contrast, the PAE increased
with repeated exposure with temafloxacin (1.8 to >5 h), but disappeared with tobramycin by the third exposure
(0.9 to 0 h). These data show that the in vitro PAE may change within a strain following multiple cycles of drug
exposure and bacterial regrowth.
The design of optimal dosage regimens for antibiotics used
in the management of infectious diseases is dependent upon
determination of pharmacokinetic and pharmacodynamic
parameters which reproducibly predict efficacy while mini-
mizing risks for the development of toxicity. Bacterial killing
rates and the postantibiotic effect (PAE) are examples of
important pharmacodynamic parameters which aid in the
optimization of dosing regimens (4).
While the PAE has often been determined following a
single "dose" or exposure, the effect of repeated antibiotic
exposures to bacteria on the PAE has not been evaluated.
Since most infections are treated with multiple doses of
antibiotics which result in several cycles of drug exposure
(and in some cases regrowth), it is important to consider the
reproducibility of the PAE in the design of dosage regimens.
The aim of the present study was to determine how the PAE
for Pseudomonas aeruginosa is affected following repeated
antibiotic exposure with three agents representative of
classes of drugs exerting a PAE: imipenem, temafloxacin,
and tobramycin.
A clinical isolate ofP. aeruginosa (strain 92) isolated from
a patient at Roger Williams General Hospital and the labo-
ratory strain P. aeruginosa ATCC 27853 were studied.
Imipenem (lot 80595) and temafloxacin (lot A-63004) were
supplied by Merck Sharp & Dohme (West Point, Pa.) and
Abbott Laboratories (Abbott Park, Ill.), respectively. To-
bramycin (lot OD29810) was obtained from Sigma Chemical
Co. (St. Louis, Mo.). Mueller-Hinton broth (Difco Labora-
tories, Detroit, Mich.) supplemented with calcium (50 mg/
liter) and magnesium (24 mg/liter) (MHB-S) was used for all
susceptibility and PAE studies. The CFU per milliliter was
determined by using unsupplemented Mueller-Hinton agar
(MHA).
Pre-exposure MICs were determined by the broth mac-
rodilution method according to the guidelines of the National
Committee for Clinical Laboratory Standards (6) by using a
starting inoculum of -5 x 105 CFU/ml (6). The MIC was
defined as the lowest concentration of antibiotic that pre-
vented visible growth following an 18-h incubation at 37°C.
* Corresponding author.
t Present address: Department of Pharmacy 1B, Detroit Receiv-
ing Hospital, Detroit, MI 48201.
Bacterial inocula were prepared from a 20-h overnight
growth of three to five colonies picked from an agar plate,
diluted 1:1,000 in MHB-S, and incubated for 3 h at 37°C to
bring the organisms into a log-linear growth phase. Five to
six replicates of antimicrobial agent-exposed cultures were
performed for each drug. The starting inoculum for each
drug-bacterium combination was adjusted to give a 1 x 106
to 1 x 107 CFU/ml in a total volume of 10 ml of MHB-S. The
concentrations of antibiotics were chosen such that a PAE of
1 to 2 h would be produced after the first cycle of drug
exposure. Pilot experiments determined that exposure to
lOx the MIC (20 Fxg/ml) of imipenem, 4x the MIC (8 ,ug/ml)
of temafloxacin, and 2x the MIC (2 ,g/ml) of tobramycin for
2 h at 37°C resulted in PAEs within this range for the test
strains. Bacteria were incubated in tubes with or without
drugs (control) for 2 h.
Following a 2-h incubation of drug plus bacteria, the tubes
were centrifuged at 1,200 x g for 15 min, and 9 ml of
supernatant was removed. The bacteria contained in the
remaining 1-ml aliquot were resuspended in 9 ml of fresh,
prewarmed, drug-free MHB-S and were gently vortexed.
This procedure was repeated three times. To ensure compa-
rability of growth patterns of the control and the drug-
exposed cultures, the control-growth tube was diluted in
drug-free MHB-S after the washing procedure to bring the
bacterial concentration in the control-growth tube to the
same level as that in the drug-exposed tube.
The effects of a second and a third cycle of drug exposure
and removal on the PAE were assessed when drug-exposed
cultures had regrown to the level of the initial inoculum prior
to the first cycle of drug exposure. One milliliter of a
concentrated stock solution of drug was added to the culture
tube containing regrowing bacteria at 6 to 8 h (second
exposure) or 14 to 16 h (third exposure). The mixture was
vortexed and incubated for 2 h. After the 2-h incubation,
drug-containing and control cultures were processed and
samples were collected as described above following the first
exposure.
The number of bacteria was quantified by removing 100 pl
from the culture at hourly intervals for the first 4 h and after
the drug was removed. Samples were serially diluted with
cold 0.9% sodium chloride, and 20 pl was plated onto MHA
in triplicate. The plates were incubated for 18 to 24 h, and the
colonies were counted. When bacterial counts were ex-
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pected to be low, 100-,ul samples were placed in 10 ml of cold
0.9% sodium chloride and were drawn through a 0.45-pm-
pore-size filter (Millipore, Danvers, Mass.) under suction.
Filters were placed aseptically on MHA and incubated for 18
to 24 h, and the colonies were counted. The lower limit of
detection of the number of bacteria for this procedure was 10
CFU/ml. The PAE was calculated from plots of CFU per
milliliter versus time by classical methods (1).
The susceptibilities of the isolates recovered during the
regrowth phase following the first through third exposure
cycles were determined by the broth macrodilution method.
The isolates were prepared for MIC testing by growing them
overnight in MHB-S, and the isolates were tested as de-
scribed above.
Imipenem produced a 2- to 3-log-unit decrease in the initial
CFU per milliliter with each exposure. The PAEs were
between 1 and 3 h for both strains and did not change with
repeated cycles of drug exposure and removal (Fig. 1). There
were no significant changes in the susceptibility of either
strain to the drug.
In contrast to imipenem, there were significant changes in
the bacterial killing and PAEs for both temafloxacin and
tobramycin with repeated drug exposure-growth cycles.
With tobramycin, bacterial killing with the third exposure
was reduced; a 4-log-unit decrease in the CFU per milliliter
was observed following the first exposure to tobramycin,
with no bactericidal activity observed following the third
exposure (Fig. 2A). While the initial exposure to tobramycin
produced a PAE of ca. 1 h, the PAE was lost by the third
exposure; this loss of a PAE was associated with an increase
in the MIC from 1 to 8 mg/liter.
A third pattern of change was observed with the fluoro-
quinolone temafloxacin. Although the initial exposure pro-
duced marked bacterial killing, a less than 1-log-unit CFU-
per-milliliter reduction was observed during the third cycle
of exposure (Fig. 2B). The bacteriostasis induced following
the third exposure resulted in a prolonged PAE that was
estimated to be over 5 h (Fig. 2B). The pre- and postexpo-
sure MICs of temafloxacin differed by only twofold.
The pharmacodynamics of antimicrobial agents have be-
come recognized as important elements for consideration in
the design of optimal drug dosage regimens. In particular,
the PAE is one pharmacodynamic parameter which has led
to the exploration of dosage regimens that use dosing inter-
vals that are extended beyond that predicted from consider-
ation of drug levels in serum and indices of drug effect, such
as the MIC. One assumption, implicit in the clinical appli-
cation of the PAE in using more prolonged dosage intervals,
is that the value of the PAE would be reproducible and
unchanged throughout a course of treatment.
The results presented in this report demonstrate that the in
vitro PAE may change following several cycles of drug
exposure and bacterial regrowth. With temafloxacin and
tobramycin, but not imipenem, the changes in the PAE
occurred as soon as the second or third cycle of drug
exposure. These classes of agents may select for drug-
resistant subpopulations ofP. aeruginosa in vitro and in vivo
(3). Although the simultaneous disappearance of a PAE and
loss of a bactericidal effect has also been noted previously
for imipenem (7), we did not observe this in our study.
In contrast, the loss of a PAE with tobramycin against P.
aeruginosa was associated with a reduced bactericidal effect
and susceptibility to drug. The changes in bacterial killing
were not consistent with the adaptive resistance that occurs
following initial exposure to aminoglycosides, as described
by Daikos et al. (2). Adaptive resistance occurs during the
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FIG. 1. PAE following repeated cycles of imipenem exposure
(exp.) and regrowth for two strains of P. aeruginosa, strain 92 (A)
and ATCC 27853 (B). Drug-exposed cultures (+) were washed and
resuspended in drug-free medium after three 2-h exposures. Control
growth cultures (0) were also washed, resuspended in drug-free
medium, and diluted (1:1,000) to provide CFU per milliliter similar
to that in drug-exposed cultures at the indicated times. Each datum
point represents the geometric mean CFU per milliliter of five to six
replicates performed over 2 or 3 different days.
early phases of aminoglycoside exposure from down-regula-
tion of drug uptake. Adaptive resistance is present immedi-
ately following the PAE, when bacterial regrowth has begun,
and ultimately disappears over several hours (2). In contrast
to the information presented above, the loss of a PAE and
the bactericidal effect with tobramycin in the present study
occurred after the period of adaptive resistance would have
been expected to have occurred. Bacteria recovered at the
end of the experiment had an eightfold reduction in their
susceptibilities to tobramycin, suggesting that selection of
stable drug-resistant subpopulations had occurred.
Variability and changes in the PAE between and within
strains have been demonstrated. It has been shown for
gram-negative bacteria that certain aminoglycosides may
variably produce a PAE (3, 5). Odenholt-Tornqvist et al. (8)
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FIG. 2. PAE following repeated cycles of drug exposure and
regrowth of P. aeruginosa 92 for tobramycin (at 2x the MIC [A])
and temafloxacin (4x the MIC [B]). See the legend to Fig. 1 for
descriptions of symbols and procedures.
have also shown changes in the pharmacodynamic effects of
beta-lactam antibiotics with exposure of bacteria to supra-
MICs of drug that are followed by periods of subinhibitory
concentrations. In contrast to these results, Vogelman et al.
(9) have confirmed the presence of an in vivo PAE after two
doses of gentamicin against Escherichia coli and Kebsiella
species in an experimental thigh infection model.
These data show the limitations of values for the in vitro
PAE when derived from a single cycle of drug exposure and
regrowth. While several studies in animal and in vitro
models of infection and in humans have demonstrated the
efficacy of single daily dosing with aminoglycosides (for
which a prolonged PAE can be shown), the actual link
between demonstration of an in vitro PAE and the efficacies
of more prolonged dosage intervals has not been proven.
The specific value of the PAE may not be useful precisely for
calculating the actual dosage interval for drug administra-
tion. Rather, the first-exposure PAE may serve as a marker
which should prompt exploration of novel dosage regimens
in established in vitro and animal models of infection and,
ultimately, in humans.
This work was sponsored in part through grants provided by
Merck Sharp & Dohme, West Point, Pa., and Abbott Laboratories,
Abbott Park, Ill.
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